Lin Chih-Ching, Chang Chao-Fu, Lai Ming-Yu, Chen Tzen-Wen, Lee Pui-Ching, Yang Wu-Chang
Division of Nephrology, Institute of Clinical Medicine and School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China.
J Am Soc Nephrol. 2007 Mar;18(3):985-92. doi: 10.1681/ASN.2006050534. Epub 2007 Jan 31.
Vascular access malfunction, usually presenting with an inadequate access flow (Qa), is the leading cause of morbidity and hospitalization in hemodialysis (HD) patients. Many methods of thermal therapy have been tried for improving Qa but with limited effects. This randomized trial was designed to evaluate the effect of far-infrared (FIR) therapy on access flow and patency of the native arteriovenous fistula (AVF). A total of 145 HD patients were enrolled with 73 in the control group and 72 in the FIR group. A WS TY101 FIR emitter was used for 40 min, and hemodynamic parameters were measured by the Transonic HD(02) monitor during HD. The Qa(1)/Qa(2) and Qa(3)/Qa(4) were defined as the Qa measured at the beginning/at 40 min later in the HD session before the initiation and at the end of the study, respectively. The incremental change of Qa in the single HD session with FIR therapy was significantly higher than that without FIR therapy (13.2 +/- 114.7 versus -33.4 +/- 132.3 ml/min; P = 0.021). In comparison with control subjects, patients who received FIR therapy for 1 yr had (1) a lower incidence (12.5 versus 30.1%; P < 0.01) and relative incidence (one episode per 67.7 versus one episode per 26.7 patient-months; P = 0.03) of AVF malfunction; (2) higher values of the following parameters, including Delta(Qa(4) - Qa(3)) (36.2 +/- 82.4 versus -12.7 +/- 153.6 ml/min; P = 0.027), Delta(Qa(3) - Qa(1)) (36.3 +/- 166.2 versus -51.7 +/- 283.1 ml/min; P = 0.035), Delta(Qa(4) - Qa(2)) (99.2 +/- 144.4 versus -47.5 +/- 244.5 ml/min; P < 0.001), and Delta(Qa(4) - Qa(2)) - Delta(Qa(3) - Qa(1)) (62.9 +/- 111.6 versus 4.1 +/- 184.5 ml/min; P = 0.032); and (3) a better unassisted patency of AVF (85.9 versus 67.6%; P < 0.01). In conclusion, FIR therapy, a noninvasive and convenient therapeutic modality, can improve Qa and survival of the AVF in HD patients through both its thermal and its nonthermal effects.
血管通路故障通常表现为通路血流量(Qa)不足,是血液透析(HD)患者发病和住院的主要原因。人们尝试了多种热疗方法来改善Qa,但效果有限。本随机试验旨在评估远红外线(FIR)疗法对自体动静脉内瘘(AVF)血流量和通畅性的影响。共纳入145例HD患者,其中对照组73例,FIR组72例。使用WS TY101 FIR发射器照射40分钟,并在HD期间通过Transonic HD(02)监测仪测量血流动力学参数。Qa(1)/Qa(2)和Qa(3)/Qa(4)分别定义为研究开始前HD疗程开始时/40分钟后以及研究结束时测量的Qa。单次HD疗程中FIR治疗组Qa的增量变化显著高于未进行FIR治疗组(13.2±114.7对-33.4±132.3 ml/min;P = 0.021)。与对照组相比,接受FIR治疗1年的患者:(1)AVF故障的发生率(12.5%对30.1%;P < 0.01)和相对发生率(每67.7患者月发生1次对每26.7患者月发生1次;P = 0.03)较低;(2)以下参数值较高,包括Delta(Qa(4) - Qa(3))(36.2±82.4对-12.7±153.6 ml/min;P = 0.027)、Delta(Qa(3) - Qa(1))(36.3±166.2对-51.7±283.1 ml/min;P = 0.035)、Delta(Qa(4) - Qa(2))(99.2±144.4对-47.5±244.5 ml/min;P < 0.001)以及Delta(Qa(4) - Qa(2)) - Delta(Qa(3) - Qa(1))(62.9±111.6对4.